Daniela Gerovska*
With approximately 1.4 million men diagnosed with prostate cancer each year around the world, PCa remains a terrifying threat to life and a source of devastating morbidity. Increased prostate-specific antigen screening and improved treatments have resulted in a significant decrease in age-specific PCa mortality in recent decades. Nonetheless, upcoming, enhanced PSA screening recommendations highlight an increasing disparity between the benefit and harm of current diagnosis/prognosis and application of radical treatment standards. To alleviate this tense situation, new powerful diagnostic and prognostic tools are unquestionably required. They should enable a more reliable early assessment of the impending threat, allowing for timely adjusted and personalised therapy and monitoring. We present here a basic study on an epigenetic screening method using Methylated DNA Immunoprecipitation.These can be used for early detection and may contribute to a new PCa epigenetic tumour classification system. Our findings show that we can isolate short, differentially methylated CpG-rich DNA fragments and combinations of them that are found in all tumours. Tumor cell-specific differential methylated CpG dinucleotide signatures are what we call them.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 